Array BioPharma Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2018
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Array Biopharma (ARRY) Misses Q4 EPS by 1c, Revenues Miss
August 14, 2018 8:01 AM EDTArray Biopharma (NASDAQ: ARRY) reported Q4 EPS of ($0.25), $0.01 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $35.44 million versus the consensus estimate of $38.73 million.
"We were thrilled to launch BRAFTOVI + MEKTOVI® for patients with BRAF-mutant melanoma in... More
